You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial

Article metrics

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trial in Progress
1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial

 

Online download statistics by month:

Online download statistics by month: October 2023 to June 2025

AbstractFullPdf
Oct 2023401
Nov 2023252027
Dec 202371014
Jan 20245004
Feb 20244606
Mar 202478014
Apr 2024116012
May 2024112010
Jun 20244808
Jul 202460012
Aug 20247205
Sep 20245003
Oct 20247005
Nov 20245407
Dec 20245006
Jan 20257208
Feb 20251508
Mar 2025005
Apr 2025009
May 2025006
Jun 2025104
Total12210174